Scoring 2 Million Prescriptions, Novo’s GLP-1 Pill Crushes Expectations
Concerned about an AI bubble? Sign up for The Daily Upside for smart and actionable market news, built…
Will Eli Lilly Be the First $2 Trillion Healthcare Stock? 3 Catalysts That Could Get It There.
Last year, Eli Lilly (NYSE: LLY) made history when it became the first healthcare company to reach a…
Novo Nordisk Expands GLP-1 Reach With Oral Ozempic And Pediatric Push
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for…
Should You Add a Healthcare Stock to Your Portfolio This Month? And Should It Be Eli Lilly (LLY)?
If you’re looking to add to your long-term stock portfolio, it can make good sense to consider a…
Can Oral Ozempic and Label Expansions Revive NVO’s Near-Term Growth?
Novo Nordisk NVO is a dominant player in the GLP-1 space, marketing its semaglutide drugs under brand names Ozempic…
Lilly’s Foundayo hits 1,390 prescriptions in debut week
April 17 (Reuters) – Eli Lilly’s newly launched obesity pill was prescribed 1,390 times in the U.S. as…
After Obtaining Approval for Its Weight Loss Pill, Is It Off to the Races for Eli Lilly Stock?
On April 1, Eli Lilly (NYSE: LLY) and its shareholders received the news they were eagerly awaiting: the…
Which of These Healthcare Stocks Is More Likely to Be a Millionaire Maker?
Picking winning stocks could lead your portfolio into millionaire territory over time — so it’s important to choose…
Eli Lilly Weight-Loss Pill Becomes Available in U.S.
Eli Lilly’s Foundayo weight-loss pill is now available in the U.S. following the Food and Drug Administration’s approval…
Global drug makers face pricing pressure as China targets affordable healthcare
Global pharmaceutical companies posted mixed earnings in China last year, with some firms warning that 2026 will be…
Trump announces 100% tariff on pharma imports – The Irish Times
Most Irish pharmaceutical exports look set to escape 100 per cent tariffs announced overnight by the Trump administration.…
Factbox-Pricing and availability of Novo, Lilly’s weight-loss drugs
April 1 (Reuters) – The U.S. Food and Drug Administration has approved Eli Lilly’s oral weight-loss drug, orforglipron,…